KR102686172B1 - Psma-표적화된 암 영상화 또는 방사선요법 동안 건강한 조직 보호를 위한 2-pmpa 전구약물 - Google Patents

Psma-표적화된 암 영상화 또는 방사선요법 동안 건강한 조직 보호를 위한 2-pmpa 전구약물 Download PDF

Info

Publication number
KR102686172B1
KR102686172B1 KR1020197032774A KR20197032774A KR102686172B1 KR 102686172 B1 KR102686172 B1 KR 102686172B1 KR 1020197032774 A KR1020197032774 A KR 1020197032774A KR 20197032774 A KR20197032774 A KR 20197032774A KR 102686172 B1 KR102686172 B1 KR 102686172B1
Authority
KR
South Korea
Prior art keywords
psma
delete delete
pmpa
group
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197032774A
Other languages
English (en)
Korean (ko)
Other versions
KR20200059187A (ko
Inventor
바바라 슬러셔
마이클 네델코비취
라나 라이스
클레멘스 크라토크윌
Original Assignee
더 존스 홉킨스 유니버시티
아다르가, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티, 아다르가, 엘엘씨 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20200059187A publication Critical patent/KR20200059187A/ko
Application granted granted Critical
Publication of KR102686172B1 publication Critical patent/KR102686172B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197032774A 2017-04-11 2018-04-11 Psma-표적화된 암 영상화 또는 방사선요법 동안 건강한 조직 보호를 위한 2-pmpa 전구약물 Active KR102686172B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
US62/484,219 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Publications (2)

Publication Number Publication Date
KR20200059187A KR20200059187A (ko) 2020-05-28
KR102686172B1 true KR102686172B1 (ko) 2024-07-17

Family

ID=63792979

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197032774A Active KR102686172B1 (ko) 2017-04-11 2018-04-11 Psma-표적화된 암 영상화 또는 방사선요법 동안 건강한 조직 보호를 위한 2-pmpa 전구약물

Country Status (11)

Country Link
US (1) US20200069706A1 (enExample)
EP (1) EP3609544B1 (enExample)
JP (3) JP2020530007A (enExample)
KR (1) KR102686172B1 (enExample)
CN (1) CN111801121B (enExample)
AU (1) AU2018250609B2 (enExample)
CA (1) CA3059741A1 (enExample)
ES (1) ES3021195T3 (enExample)
IL (1) IL269969B2 (enExample)
SG (1) SG11201909513QA (enExample)
WO (1) WO2018191376A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
HUE066137T2 (hu) 2013-10-18 2024-07-28 Novartis Ag A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
JP6464166B2 (ja) 2013-11-14 2019-02-06 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 陽電子放出断層撮影用の化合物
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
EP3853213A4 (en) * 2018-09-21 2022-07-06 Endocyte, Inc. Shielding agents and their use
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
KR20230002831A (ko) * 2020-04-29 2023-01-05 노파르티스 아게 Psma 결합 리간드의 방사성 표지 방법 및 이의 키트
CA3194592A1 (en) * 2020-10-01 2022-04-07 Neil H. Bander Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
WO2025029946A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
US10172873B2 (en) 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors
JP2017530109A (ja) * 2014-09-08 2017-10-12 モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kristell L.S. Chatalic 외. Theranostics. 2016, Vol. 6, Issue 6, pp. 849-861*

Also Published As

Publication number Publication date
WO2018191376A3 (en) 2018-12-27
AU2018250609A1 (en) 2019-10-31
AU2018250609B2 (en) 2024-05-09
US20200069706A1 (en) 2020-03-05
EP3609544C0 (en) 2025-04-09
EP3609544A2 (en) 2020-02-19
JP2020530007A (ja) 2020-10-15
IL269969B2 (en) 2023-04-01
CN111801121A (zh) 2020-10-20
WO2018191376A2 (en) 2018-10-18
EP3609544B1 (en) 2025-04-09
IL269969A (en) 2022-12-01
JP2023093545A (ja) 2023-07-04
ES3021195T3 (en) 2025-05-26
JP2025028897A (ja) 2025-03-05
CN111801121B (zh) 2023-12-01
EP3609544A4 (en) 2020-12-23
KR20200059187A (ko) 2020-05-28
CA3059741A1 (en) 2018-10-18
SG11201909513QA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
KR102686172B1 (ko) Psma-표적화된 암 영상화 또는 방사선요법 동안 건강한 조직 보호를 위한 2-pmpa 전구약물
US20230147035A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP7073270B2 (ja) 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤
CN109476655B (zh) 靶向碳酸酐酶ix的核成像剂和放射治疗剂及其用途
JP2020522506A5 (enExample)
US10857246B2 (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
US10717750B2 (en) 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
HK40037500A (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
HK40037500B (zh) 在psma靶向癌症成像或放疗期间用於健康组织保护的2-pmpa前药
HK40006359B (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof
HK40006359A (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210409

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230519

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231223

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230519

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20231223

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230817

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210409

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20240626

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240715

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240715

End annual number: 3

Start annual number: 1

PG1601 Publication of registration